文献速递头颈外科

FDA批准的头颈癌免疫治疗与化疗药物的私人付款方议价价格

Private Payer-Negotiated Rates for FDA-Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-03-01

该横断面研究分析了美国新闻与世界报道耳鼻咽喉科排名前50家医院的价格透明文件,量化私人付款方对头颈鳞状细胞癌(HNSCC)治疗药物的支付价格,并识别与价格变异相关的医院层面因素。结果显示24家(48%)医院报告了至少1种药物价格,新型生物制剂显著贵于传统化疗药,价格加价率从109%至530%不等,340B资格及东北/西部地理位置的医院加价较低。

要点

  • 24家(48%)医院报告了至少1种药物价格,价格不披露仍是显著问题。
  • 新型生物制剂价格显著高于传统化疗药物。
  • 340B资格及东北/西部地区医院的价格加价较低。

核心结论

  • 价格不披露在医院中仍是显著问题。
  • 新型生物制剂较传统化疗药物更昂贵。
  • 医院间价格差异显著,340B医院及位于东北和西部地区的医院加价较低。
  • 价格透明是否能带来更统一定价或降低治疗成本尚待观察。

研究设计与样本

  • 横断面研究,分析美国新闻与世界报道耳鼻咽喉科排名前50家医院的价格透明文件,时间范围为2021年12月至2022年6月。
  • 分析药物包括FDA批准的HNSCC治疗药物:帕博利珠单抗、纳武利尤单抗、西妥昔单抗、顺铂、卡铂和紫杉醇。

主要发现

  • 24家(48%)医院报告了样本中至少1种药物的价格。
  • 新型生物制剂显著贵于传统化疗药物。
  • 按批准的用药方案,样本中所有生物制剂的年成本相似。
  • 价格加价率范围为109%(帕博利珠单抗、纳武利尤单抗)至530%(卡铂)。
  • 医院间价格变异最大的是紫杉醇(样本中最便宜药物),变异最小的是帕博利珠单抗(样本中最贵药物)。

关键数值与推荐

  • 价格加价率:帕博利珠单抗和纳武利尤单抗为109%,卡铂为530%。
  • 340B资格与东北/西部地区位置与较低价格加价相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the price that private payers pay hospitals for head and neck squamous cell carcinoma (HNSCC) treatments and identify hospital-level factors associated with price variation. STUDY DESIGN: Cross-sectional study. SETTING: Price transparency files. METHODS: Files from the top 50 hospitals in otolaryngology according to the US News and World Report were analyzed between December 2021 and June 2022. This study analyzed the following Food and Drug Administration-approved HNSCC therapies: pembrolizumab, nivolumab, cetuximab, cisplatin, carboplatin, and paclitaxel. RESULTS: Twenty-four (48%) hospitals reported prices for at least 1 medication in our sample. Newer biologics were significantly more expensive than traditional chemotherapeutic agents. Given approved medication regimens, all biologics in our sample have similar annual costs. Price markups over acquisition costs ranged between 109% (pembrolizumab, nivolumab) and 530% for carboplatin. Across hospitals, prices varied the most for paclitaxel, the cheapest medication in our sample, and prices varied the least for pembrolizumab the most expensive medication in our sample. Hospital 340B status and geographic location in the northeast/west are associated with lower price markups. CONCLUSION: Price nondisclosure remains a significant problem among hospitals. Newer biological medications are more expensive when compared to traditional chemotherapeutic agents. Prices vary significantly across hospitals, with lower price markups observed in 340B hospitals as well as hospitals located in the geographic northeast and west. It remains to be seen if price transparency will lead to more uniform pricing or lower costs of treatments.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Talwar A, Kim S, Yu S, et al. Private Payer-Negotiated Rates for FDA-Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents. Otolaryngol Head Neck Surg. 2023. PMID: 36856039. doi:10.1002/ohn.308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。